Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Navigation/Suche

• Forscher*innen.
• Institutionen.
• Projekte.
• Publikationen.
• Partner.
• Geldgeber.
• Ausstattung.
• Knowhow.
• Forschungsfelder.

Publikationen

Suchbegriffe: COLORECTAL NEOPLASMS - DRUG THERAPY , . Treffer: 33

2020

Moik, F; Posch, F; Grilz, E; Scheithauer, W; Pabinger, I; Prager, G; Ay, C Haemostatic biomarkers for prognosis and prediction of therapy response in patients with metastatic colorectal cancer.
Thromb Res. 2020; 187:9-17 Doi: 10.1016/j.thromres.2020.01.002 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2019

Barth, DA; Riedl, JM; Posch, F; Smolle, MA; Kasparek, AK; Niedrist, T; Szkandera, J; Stöger, H; Pichler, M; Stotz, M; Gerger, A Critical evaluation of platelet size as a prognostic biomarker in colorectal cancer across multiple treatment settings: a retrospective cohort study.
Clin Transl Oncol. 2019; 21(8):1034-1043 Doi: 10.1007/s12094-019-02037-7 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2017

Goblirsch, M; Richtig, G; Slaby, O; Berindan-Neagoe, I; Gerger, A; Pichler, M MicroRNAs as a tool to aid stratification of colorectal cancer patients and to guide therapy.
Pharmacogenomics. 2017; 18(10):1027-1038 Doi: 10.2217/pgs-2017-0004
Web of Science PubMed FullText FullText_MUG

 

Riedl, JM; Posch, F; Bezan, A; Szkandera, J; Smolle, MA; Winder, T; Rossmann, CH; Schaberl-Moser, R; Pichler, M; Stotz, M; Stöger, H; Gerger, A Patterns of venous thromboembolism risk in patients with localized colorectal cancer undergoing adjuvant chemotherapy or active surveillance: an observational cohort study.
BMC Cancer. 2017; 17(1):415-415 Doi: 10.1186/s12885-017-3392-4 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Schütte, M; Risch, T; Abdavi-Azar, N; Boehnke, K; Schumacher, D; Keil, M; Yildiriman, R; Jandrasits, C; Borodina, T; Amstislavskiy, V; Worth, CL; Schweiger, C; Liebs, S; Lange, M; Warnatz, HJ; Butcher, LM; Barrett, JE; Sultan, M; Wierling, C; Golob-Schwarzl, N; Lax, S; Uranitsch, S; Becker, M; Welte, Y; Regan, JL; Silvestrov, M; Kehler, I; Fusi, A; Kessler, T; Herwig, R; Landegren, U; Wienke, D; Nilsson, M; Velasco, JA; Garin-Chesa, P; Reinhard, C; Beck, S; Schäfer, R; Regenbrecht, CR; Henderson, D; Lange, B; Haybaeck, J; Keilholz, U; Hoffmann, J; Lehrach, H; Yaspo, ML Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors.
Nat Commun. 2017; 8(2):14262-14262 Doi: 10.1038/ncomms14262 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2016

Bonin, S; Donada, M; Bussolati, G; Nardon, E; Annaratone, L; Pichler, M; Chiaravalli, AM; Capella, C; Hoefler, G; Stanta, G A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients.
Tumour Biol. 2016; 37(6):7295-7303 Doi: 10.1007/s13277-015-4543-3
Web of Science PubMed FullText FullText_MUG

 

Pehserl, AM; Ress, AL; Stanzer, S; Resel, M; Karbiener, M; Stadelmeyer, E; Stiegelbauer, V; Gerger, A; Mayr, C; Scheideler, M; Hutterer, GC; Bauernhofer, T; Kiesslich, T; Pichler, M Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells.
Int J Mol Sci. 2016; 17(12): Doi: 10.3390/ijms17122011 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Perakis, SO; Thomas, JE; Pichler, M Non-coding RNAs Enabling Prognostic Stratification and Prediction of Therapeutic Response in Colorectal Cancer Patients.
Adv Exp Med Biol. 2016; 937(4):183-204 Doi: 10.1007/978-3-319-42059-2_10
Web of Science PubMed FullText FullText_MUG

 

2015

Bochis, OV; Irimie, A; Pichler, M; Berindan-Neagoe, I The role of Skp2 and its substrate CDKN1B (p27) in colorectal cancer.
J Gastrointestin Liver Dis. 2015; 24(2):225-234 Doi: 10.15403/jgld.2014.1121.242.skp2 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Eisner, F; Pichler, M; Goletz, S; Stoeger, H; Samonigg, H A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options.
J Clin Pathol. 2015; 68(12):1044-1046 Doi: 10.1136/jclinpath-2015-202996 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Kaczirek, K; Ciuleanu, TE; Vrbanec, D; Marton, E; Messinger, D; Liegl-Atzwanger, B; Wrba, F; Knittelfelder, R; Lindner, E; Zielinski, CC; Streubel, B; Brodowicz, T FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Clin Colorectal Cancer. 2015; 14(2):91-98 Doi: 10.1016/j.clcc.2014.12.003
Web of Science PubMed FullText FullText_MUG

 

Thomas, J; Ohtsuka, M; Pichler, M; Ling, H MicroRNAs: Clinical Relevance in Colorectal Cancer.
Int J Mol Sci. 2015; 16(12):28063-28076 Doi: 10.3390/ijms161226080 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2014

Benhaim, L; Gerger, A; Bohanes, P; Paez, D; Wakatsuki, T; Yang, D; Labonte, MJ; Ning, Y; El-Khoueiry, R; Loupakis, F; Zhang, W; Laurent-Puig, P; Lenz, HJ Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy.
Pharmacogenomics J. 2014; 14(2):135-141 Doi: 10.1038/tpj.2013.21
Web of Science PubMed FullText FullText_MUG

 

Mohan, S; Heitzer, E; Ulz, P; Lafer, I; Lax, S; Auer, M; Pichler, M; Gerger, A; Eisner, F; Hoefler, G; Bauernhofer, T; Geigl, JB; Speicher, MR Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing.
PLoS Genet. 2014; 10(3):e1004271-e1004271 Doi: 10.1371/journal.pgen.1004271 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Pichler, M; Winter, E; Ress, AL; Bauernhofer, T; Gerger, A; Kiesslich, T; Lax, S; Samonigg, H; Hoefler, G miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.
J Clin Pathol. 2014; 67(3):198-203 Doi: 10.1136/jclinpath-2013-201904
Web of Science PubMed FullText FullText_MUG

 

Ress, AL; Stiegelbauer, V; Schwarzenbacher, D; Deutsch, A; Perakis, S; Ling, H; Ivan, C; Calin, GA; Rinner, B; Gerger, A; Pichler, M Spinophilin expression determines cellular growth, cancer stemness and 5-flourouracil resistance in colorectal cancer.
Oncotarget. 2014; 5(18):8492-8502 Doi: 10.18632/oncotarget.2329 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Smolle, M; Uranitsch, S; Gerger, A; Pichler, M; Haybaeck, J Current status of long non-coding RNAs in human cancer with specific focus on colorectal cancer.
Int J Mol Sci. 2014; 15(8):13993-14013 Doi: 10.3390/ijms150813993 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Stiegelbauer, V; Perakis, S; Deutsch, A; Ling, H; Gerger, A; Pichler, M MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.
World J Gastroenterol. 2014; 20(33):11727-11735 Doi: 10.3748/wjg.v20.i33.11727 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2012

Dijkstra, JR; Opdam, FJ; Boonyaratanakornkit, J; Schönbrunner, ER; Shahbazian, M; Edsjö, A; Hoefler, G; Jung, A; Kotsinas, A; Gorgoulis, VG; Lpez-Ros, F; de Stricker, K; Rouleau, E; Biesmans, B; van Krieken, JH Implementation of formalin-fixed, paraffin-embedded cell line pellets as high-quality process controls in quality assessment programs for KRAS mutation analysis.
J Mol Diagn. 2012; 14(3):187-191 Doi: 10.1016/j.jmoldx.2012.01.002 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Pichler, M; Winter, E; Stotz, M; Eberhard, K; Samonigg, H; Lax, S; Hoefler, G; Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer.
Br J Cancer. 2012; 106(11):1826-1832 Doi: 10.1038/bjc.2012.175 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2011

Gerger, A; El-Khoueiry, A; Zhang, W; Yang, D; Singh, H; Bohanes, P; Ning, Y; Winder, T; Labonte, MJ; Wilson, PM; Benhaim, L; Paez, D; El-Khoueiry, R; Absenger, G; Lenz, HJ Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
Clin Cancer Res. 2011; 17(17):5783-5792 Doi: 10.1158/1078-0432.CCR-11-1115 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Mikalauskas, S; Mikalauskiene, L; Bruns, H; Nickkholgh, A; Hoffmann, K; Longerich, T; Strupas, K; Büchler, MW; Schemmer, P Dietary glycine protects from chemotherapy-induced hepatotoxicity.
Amino Acids. 2011; 40(4):1139-1150 Doi: 10.1007/s00726-010-0737-6
Web of Science PubMed FullText FullText_MUG

 

Resch, G; Schaberl-Moser, R; Kier, P; Kopetzky, G; Scheithauer, W; Sliwa, T; Greil, R; Nösslinger, T; Mayrbäurl, B; Thaler, J Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safe.
Ann Oncol. 2011; 22(2): 486-487. Doi: 10.1093/annonc/mdq744 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2010

Winder, T; Zhang, W; Yang, D; Ning, Y; Bohanes, P; Gerger, A; Wilson, P; Pohl, A; Mauro, DJ; Langer, C; Rowinsky, EK; Lenz, HJ Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients.
Clin Cancer Res. 2010; 16(22):5591-5602 Doi: 10.1158/1078-0432.CCR-10-2092 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Zhang, W; Azuma, M; Lurje, G; Gordon, MA; Yang, D; Pohl, A; Ning, Y; Bohanes, P; Gerger, A; Winder, T; Hollywood, E; Danenberg, KD; Saltz, L; Lenz, HJ Molecular Predictors of Combination Targeted Therapies (Cetuximab, Bevacizumab) in Irinotecan-Refractory Colorectal Cancer (BOND-2 Study).
Anticancer Res. 2010; 30(10):4209-4217
Web of Science PubMed

 

2008

van Krieken, JH; Jung, A; Kirchner, T; Carneiro, F; Seruca, R; Bosman, FT; Quirke, P; Fléjou, JF; Plato Hansen, T; de Hertogh, G; Jares, P; Langner, C; Hoefler, G; Ligtenberg, M; Tiniakos, D; Tejpar, S; Bevilacqua, G; Ensari, A KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.
Virchows Arch. 2008; 453(5): 417-431. Doi: 10.1007/s00428-008-0665-y [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2007

D'Angelica, M; Kornprat, P; Gonen, M; Chung, KY; Jarnagin, WR; DeMatteo, RP; Fong, Y; Kemeny, N; Blumgart, LH; Saltz, LB Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study.
Ann Surg Oncol. 2007; 14(2):759-765 Doi: 10.1245/s10434-006-9074-0
Web of Science PubMed FullText FullText_MUG

 

Kornprat, P; Jarnagin, WR; Gonen, M; DeMatteo, RP; Fong, Y; Blumgart, LH; D'Angelica, M Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy.
Ann Surg Oncol. 2007; 14(3):1151-1160 Doi: 10.1245/s10434-006-9068-y
Web of Science PubMed FullText FullText_MUG

 

2005

Filipits, M; Pohl, G; Rudas, M; Dietze, O; Lax, S; Grill, R; Pirker, R; Zielinski, CC; Hausmaninger, H; Kubista, E; Samonigg, H; Jakesz, R Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group.
J Clin Oncol. 2005; 23(6):1161-1168 Doi: 10.1200/JCO.2005.03.033 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2002

Eckel, F; Schmelz, R; Adelsberger, H; Erdmann, J; Quasthoff, S; Lersch, C Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study
DEUT MED WOCHENSCHR 2002 127: 78-82. Doi: 10.1055/s-2002-19594
Web of Science PubMed FullText FullText_MUG

 

Lersch, C; Schmelz, R; Eckel, F; Erdmann, J; Mayr, M; Schulte-Frohlinde, E; Quasthoff, S; Grosskreutz, J; Adelsberger, H Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer.
Clin Colorectal Cancer. 2002; 2(1): 54-58. Doi: 10.3816/CCC.2002.n.011
PubMed FullText FullText_MUG

 

1999

Hausmaninger, H; Moser, R; Samonigg, H; Mlineritsch, B; Schmidt, H; Pecherstorfer, M; Fridrik, M; Kopf, C; Nitsche, D; Kaider, A; Ludwig, H Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study.
Eur J Cancer. 1999; 35(3):380-385 Doi: 10.1016%2FS0959-8049%2898%2900397-9
Web of Science PubMed FullText FullText_MUG Google Scholar

 

1996

Cunningham, D; Zalcberg, JR; Rath, U; Oliver, I; van Cutsem, E; Svensson, C; Seitz, JF; Harper, P; Kerr, D; Perez-Manga, G Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
Ann Oncol. 1996; 7(9):961-965 Doi: 10.1093/oxfordjournals.annonc.a010800 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

↑ Seitenanfang / Navigation

© Med Uni Graz • Impressum